Cost-Effectiveness Analysis of Antibiotic Use in Patients with Chronic Obstructive Pulmonary Desease (COPD)
DOI:
https://doi.org/10.59653/jimat.v3i01.1474Keywords:
Cost-effectiveness, Antibiotics, Acute exacerbation of COPDAbstract
Chronic obstructive pulmonary disease (COPD) is a disease with airway limitations that are not completely reversible due to harmful substances or gases. The most common cause of acute exacerbations of COPD is bacterial infection, so treatment that can be done is to use antibiotics. Ineffective drug therapy will affect the effectiveness and costs incurred by patients. The purpose of this study is to find out how cost-effective and antibiotic treatment are in patients with acute exacerbations of COPD. This study uses an observational descriptive method with retrospective data collection based on medical record data and the cost of using antibiotics for Chronic Obstructive Pulmonary Disease (COPD) acute exacerbations of hospitalization at hospitals. Dr. M. Djamil Padang in 2019-2021. The calculation result with the lowest CER was the combination of levofloxacin and ceftriaxone of Rp. 323.6 and an outcome value of 100%. It can be concluded that the most effective use of antibiotic therapy models in COPD patients with acute exacerbations is the combination of levofloxacin and ceftriaxone.
Downloads
References
Andayani TM. (2013). Pharmacoeconomics: Principles and Methodologies. Knowledge Exchange.
Baharutan, Kezia Novita, Fatma Walil, and Adeanne Wullur. 2015. Bacterial Sensitivity Test Isolated from Sputum of Patients with Chronic Bronchitis Undergoing Outpatient Treatment at Prof. Dr. R. D. Kandou Manado Hospital to Antibiotics Ampicillin, Erythromycin, and Ciprofloxacin. Pharmacon Pharmaceutical Scientific Journal. Vol 4. No 4.
Danusantoso, H. 2000. Pulmonary Disease Science. Hypocrates. Jakarta.
Dipiro, J et al. 2011. Pharmacotherapy 8th Edition. The McGrow-Hill companies, US
Directorate General of Pharmaceutical Development and Medical Devices. (2013). Guidelines for the Implementation of Pharmacoeconomic Studies. Ministry of Health of the Republic of Indonesia.
Drummond, M. F. 1999. An Introduction to Health Economics. UK: Brookwood Medical Publications. Page 46.
Handayani, F. W., Muhtadi, A., Pharmacy, F., Padjadjaran, U., Dara, T., Manis, K., & Active, S. (2013). Pharmacoeconomics Studies Underlying Treatment Selection in Indonesia. Pharmacology, 4, 1–15.
Ministry of Health, R.I. 2013. Basic Health Research (RISKESDAS). Ministry of Health of the Republic of Indonesia.
Marta, N. A., Andrini, F., Saad, A. 2014. Identification of bakeries in sputum patients with chronic obstructive pulmonary disease acute exacerbations at Arifin Achmad Hospital, Riau Province. JOM FK. 1;2.
Marta N, Azizman F, Saadetal. 2014. Identification of Sputum Bacteria in Acute CKD Exacerbation Patients at Arifin Achmad Hospital, Riau Province. JOM FK. Volume 1 Number 2.
Nalang, A. 2018. ‖Cost-Effectiveness Analysis of Pneumonia Treatment Using Seftriaxone and Sefotaksim Antibiotics at Prof. Dr. RD Kandou Manado Hospital‖. PHARMACON, 7(3). p.322-323
Okky SP, Rizky A, Ivan SP, Cherry R, et al, 2014., Analysis of minimizing the cost of empiric antibiotic use in patients with sepsis who are sources of respiratory infection. JFKI. 2014. 3(1): 10-17.
Sethi S, Evans N, Grant BJ, Murphy TF. 2002. New strain of bacteria and exacerbation of chroic obstructive pulmonary disease. N engl J Med. Volume 15 Number 7.
Sloane. 2004. Anatomy and Physiology for Beginners. Jakarta: EGC. Page 245.
Suradi, Yusup Subagio, Reviono and Harsini. 2012. The Relationship Between Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) and Sputu, Bacterial Culture Results at Dr. Moewardi Hospital, Surakarta. Indonesian Respirology: Volume 32 Number 4.
Veryanti, P. R., Wulandari, A. 2020. Cost-Effective Analysis of Bronchodilator Use Compared to Bronchodilator-Corticosteroid Combination in Patients With Chronic Obstructive Pulmonary Disease (COPD). Udayana Pharmaceutical Journal, Vol 9, No 1, Year 2020, 13-18.
WHO. (2018). Chronic Respiratory Diseases: Burden of COPD. www.who.int/repiratory/copd/burden/en/
Downloads
Published
How to Cite
License
Copyright (c) 2025 Puspa Pameswari, Mimi Aria, Aminah Zuhriah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
